Archives of Dermatological Research

, Volume 296, Issue 1, pp 6–11 | Cite as

Pharmacokinetics and safety of imiquimod 5% cream in the treatment of actinic keratoses of the face, scalp, or hands and arms

  • Lester I. HarrisonEmail author
  • Shari L. Skinner
  • Thomas C. Marbury
  • Mary L. Owens
  • Sarala Kurup
  • Scott McKane
  • Robert J. Greene
Original Paper


The safety and efficacy of imiquimod 5% cream is being evaluated for the treatment of dysplastic lesions of the epidermis (actinic keratoses, AK). The objective of this clinical study was to describe the pharmacokinetics and safety of topical imiquimod during multiple dosing of AK subjects. A total of 58 adult subjects with 5 to 20 AK lesions at the treatment site applied imiquimod cream three times per week for up to 16 weeks as follows: 12 males and 11 females applied 12.5 mg imiquimod to the face; 11 males applied 25 mg to the entire balding area of the scalp; and 12 males and 12 females applied 75 mg to both hands and forearms. Pharmacokinetics and safety were assessed after the first and last doses, as well as biweekly. Imiquimod and its metabolites were measured in the serum and urine using sensitive liquid chromatography/mass spectrometry methods. Less than 0.6% of the applied doses was recovered in the urine of all subjects. Serum imiquimod levels were low, reflecting minimal dermal absorption, and increased with dose, although not proportionally. Peak levels at the end of dosing were 0.1, 0.2, and 1.6 ng/ml for the face, scalp, and hands/arms groups, respectively. A two- to fourfold accumulation was seen at the end of dosing. Local application site reactions were the most common adverse event, reported by approximately 50% of the subjects in each treatment group. The small number of systemic adverse events, including ‘flu-like symptoms, were mostly mild and did not show a dose response. Thus, minimal systemic absorption and good safety margins for topical imiquimod were seen in AK subjects with doses as high as 75 mg three times per week for 16 weeks.


Actinic keratosis Imiquimod Immunomodulator Pharmacokinetics Safety 



Actinic keratosis


2′5′-Oligoadenylate synthetase


Area under the concentration-time curve


Maximum serum concentration




Interleukin-1 receptor antagonist


Maximum change from baseline value



The authors would like to acknowledge the following individuals who contributed to this study report: Sharon Parrish, Nanda Gosala, Jim Lee, Bruce Ekholm, Adele Hoglin, Paula Myhre, Sagar Kawle, Anthony Pierce, Kirsten Watne and Debra Kielhold from 3 M Pharmaceuticals; Simone Jones from SFBC Fort Myers; and Tammy Johnson from Orlando Clinical Research Center. This study (1402-IMIQ) was sponsored by 3 M Pharmaceuticals.


  1. 1.
    Frost CA, Green AC (1994) Epidemiology of solar keratoses. Br J Dermatol 131:455–464PubMedGoogle Scholar
  2. 2.
    Callen JP, Bickers DR, Moy RL (1997) Actinic keratoses. J Am Acad Dermatol 36:650–653PubMedGoogle Scholar
  3. 3.
    Gupta AK, Browne M, Bluhm R (2002) Imiquimod: a review. J Cutan Med Surg 6:554–560PubMedGoogle Scholar
  4. 4.
    Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA (1999) Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunol 21:1–14Google Scholar
  5. 5.
    Bogdan C (2000) The function of type I interferons in antimicrobial immunity. Curr Opin Immunol 12:419–424PubMedGoogle Scholar
  6. 6.
    Schon M, Bong AB, Drewniok C, Herz J, Geilen CC, Reifenberger B, Slade HR, Gollnick H, Schon MP (2003) Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 95:1138–1149Google Scholar
  7. 7.
    Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, Christophers E (2002) A randomized double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 138:1498–1502PubMedGoogle Scholar
  8. 8.
    Salasche SJ, Levine N, Morrison L (2002) Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 47:571–577PubMedGoogle Scholar
  9. 9.
    Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL (2004) Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol (in press)Google Scholar
  10. 10.
    Stockfleth E, Trefzer U, Garcia-Bartels C, Wegner T, Schmook T, Sterry W (2003) The use of Toll-like receptor-7 agonist in the treatment of basal cell carcinoma: an overview. Br J Dermatol 149 [Suppl 66]:53–56Google Scholar
  11. 11.
    Sauder DN, Skinner RB, Fox TL, Owens ML (2003) Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. Sex Transm Dis 30:124–128PubMedGoogle Scholar
  12. 12.
    Gollnick H, Barasso R, Jappe U, Ward K, Eul A, Carey-Yard M, Milde K (2001) Safety and efficacy of imiquimod 5% cream in treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 12:22–28CrossRefPubMedGoogle Scholar
  13. 13.
    O’Mahony C, Law C, Gollnick HP, Marini M (2001) New patient-applied therapy for anogenital warts is related favorably to patients. Int J STD AIDS 12:565–570PubMedGoogle Scholar
  14. 14.
    Owens ML, Bridson WE, Smith SL, Myers JA, Fox TL, Wells TM (1998) Percutaneous penetration of Aldara cream, 5%, during the topical treatment of genital and perianal warts. Prim Care Update Ob Gyns 5:151CrossRefGoogle Scholar
  15. 15.
    McQuinn RL, Machacek JH, Draper AM, Myhre PE, Carlson GL, Wells DA (1994) Use of Empore extraction disks for preparative purification and concentration of imiquimod and metabolites from large volumes of urine. Pharm Res [Suppl] 11:S24Google Scholar
  16. 16.
    Soria I, Myhre P, Horton V, Ellefson P, McCarville S, Schmitt K, Owens M (2000) Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther 38:476–481PubMedGoogle Scholar
  17. 17.
    Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatol 36 [Suppl 1]:S237–244Google Scholar
  18. 18.
    Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S (2002) Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3:196–200CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Lester I. Harrison
    • 1
    Email author
  • Shari L. Skinner
    • 2
  • Thomas C. Marbury
    • 3
  • Mary L. Owens
    • 4
  • Sarala Kurup
    • 1
  • Scott McKane
    • 4
  • Robert J. Greene
    • 1
  1. 1.Department of Pharmacokinetics and Drug Metabolism3 M PharmaceuticalsSt. PaulUSA
  2. 2.SFBC Fort Myers IncFort MyersUSA
  3. 3.Orlando Clinical Research CenterOrlandoUSA
  4. 4.Department of Medical Affairs3 M PharmaceuticalsSt. PaulUSA

Personalised recommendations